Bausch Health Cos Inc. $BHC Stock Holdings Boosted by Lido Advisors LLC

Lido Advisors LLC raised its stake in shares of Bausch Health Cos Inc. (NYSE:BHC) by 421.6% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 372,508 shares of the company’s stock after purchasing an additional 301,098 shares during the period. Lido Advisors LLC owned 0.10% of Bausch Health Cos worth $2,172,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Paulson & CO. Inc. purchased a new stake in shares of Bausch Health Cos during the second quarter worth about $361,151,000. MFN Partners Management LP purchased a new position in Bausch Health Cos in the 2nd quarter valued at about $29,580,000. Royal Bank of Canada lifted its stake in Bausch Health Cos by 24.9% in the 1st quarter. Royal Bank of Canada now owns 11,363,498 shares of the company’s stock valued at $61,362,000 after buying an additional 2,262,894 shares in the last quarter. Man Group plc purchased a new position in Bausch Health Cos in the 2nd quarter valued at about $7,157,000. Finally, Chicago Partners Investment Group LLC boosted its holdings in Bausch Health Cos by 6,366.3% in the 3rd quarter. Chicago Partners Investment Group LLC now owns 757,203 shares of the company’s stock worth $4,876,000 after buying an additional 745,493 shares during the last quarter. Institutional investors and hedge funds own 78.65% of the company’s stock.

Insiders Place Their Bets

In other news, insider Aimee Lenar sold 36,827 shares of the business’s stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $7.03, for a total transaction of $258,893.81. Following the transaction, the insider directly owned 334,853 shares in the company, valued at $2,354,016.59. The trade was a 9.91% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 20.67% of the stock is owned by company insiders.

Bausch Health Cos Stock Performance

Shares of NYSE:BHC traded up $0.10 during midday trading on Friday, hitting $8.36. The company’s stock had a trading volume of 2,339,973 shares, compared to its average volume of 4,769,318. The business’s 50 day simple moving average is $6.57 and its 200 day simple moving average is $5.80. The company has a market cap of $3.13 billion, a P/E ratio of -3.65 and a beta of 0.30. Bausch Health Cos Inc. has a 12-month low of $4.33 and a 12-month high of $9.04.

Bausch Health Cos (NYSE:BHC) last announced its quarterly earnings data on Wednesday, October 28th. The company reported $1.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.25 by $0.52. Bausch Health Cos had a negative net margin of 7.57% and a negative return on equity of 401.73%. The company had revenue of $2.90 billion during the quarter, compared to analysts’ expectations of $2.72 billion. On average, sell-side analysts predict that Bausch Health Cos Inc. will post 4.53 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms have commented on BHC. Royal Bank Of Canada boosted their price objective on Bausch Health Cos from $9.00 to $10.00 and gave the stock a “sector perform” rating in a research note on Thursday, October 29th. Wall Street Zen upgraded Bausch Health Cos from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 1st. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Bausch Health Cos in a research note on Thursday, October 29th. Jefferies Financial Group boosted their price target on Bausch Health Cos from $6.50 to $8.00 and gave the stock a “hold” rating in a research report on Thursday, October 29th. Finally, Zacks Research cut Bausch Health Cos from a “strong-buy” rating to a “hold” rating in a research report on Thursday, November 5th. Six analysts have rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Reduce” and a consensus price target of $8.75.

Bausch Health Cos Profile

Bausch Health Companies Inc. is a global specialty pharmaceutical and medical products company headquartered in Laval, Quebec. It develops, manufactures and markets prescription medicines, over-the-counter products and medical devices, with businesses spanning eye health, gastroenterology, dermatology, neurology and aesthetics. Its portfolio includes Salix products for gastrointestinal conditions, Ortho Dermatologics treatments for skin conditions and Solta Medical aesthetic devices. Bausch Health also retains a controlling ownership interest in Bausch + Lomb, a publicly traded eye-health company whose products include contact lenses, lens care products, pharmaceuticals and surgical devices.